DEFAST

Therapeutic Group: Anti-Diabetic Drugs Chemical Composition: Pioglitazone Hydrochloride License by : Unipharma Dosage form: Tablets
Information about DEFAST Dosage:

Monotherapy: 15 to 30 mg once daily. In case of patients who respond inadequately to the initial dose, the dose can be increased up to 45 mg once daily. In case of patients not responding adequately to monotherapy: Combination therapy should be considere



Composition:

Each tablet contains 15 or 30 mg Pioglitazone as Pioglitazone HCl.



Indications and usage:

DEFAST Tablets are indicated for the treatment of : - Diabetes type 2 as monotherapy : adjunct to diet and exercise, to improve glycemic control. - Diabetes type 2 as combination therapy with sulfonylurea, Metformin, or insulin: when diet, exercise and mo



Package:

Box Contains 20 or 30 tablets